Eculizumab administration for myasthenia gravis also stabilizes thrombogenicity of catastrophic antiphospholipid syndrome

ConclusionsEculizumab can be effective for controlling multiple complement-mediated pathophysiology.

Source: Clinical and Experimental Neuroimmunology - April 23, 2024 Category: Neurology Authors: Sunao Takahashi, Nobuo Sanjo, Ryuji Koike, Takanori Yokota Tags: CASE REPORT Source Type: research